SE9600683D0 - Azabicyclic esters of carbamic acids useful in therapy - Google Patents

Azabicyclic esters of carbamic acids useful in therapy

Info

Publication number
SE9600683D0
SE9600683D0 SE9600683A SE9600683A SE9600683D0 SE 9600683 D0 SE9600683 D0 SE 9600683D0 SE 9600683 A SE9600683 A SE 9600683A SE 9600683 A SE9600683 A SE 9600683A SE 9600683 D0 SE9600683 D0 SE 9600683D0
Authority
SE
Sweden
Prior art keywords
alkyl
halogen
hydrogen
therapy
och3
Prior art date
Application number
SE9600683A
Other languages
English (en)
Swedish (sv)
Inventor
John Macor
Edwin Wu
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE9600683A priority Critical patent/SE9600683D0/xx
Publication of SE9600683D0 publication Critical patent/SE9600683D0/xx
Priority to ZA9701082A priority patent/ZA971082B/xx
Priority to ARP970100618A priority patent/AR005876A1/es
Priority to IDP970487A priority patent/ID15969A/id
Priority to SK1027-98A priority patent/SK102798A3/sk
Priority to CA002246051A priority patent/CA2246051A1/en
Priority to KR1019980706579A priority patent/KR19990087184A/ko
Priority to CN97192461A priority patent/CN1063749C/zh
Priority to HU9901273A priority patent/HUP9901273A3/hu
Priority to PCT/SE1997/000294 priority patent/WO1997030998A1/en
Priority to JP9530075A priority patent/JP2000505452A/ja
Priority to AT97905544T priority patent/ATE219081T1/de
Priority to IL12562097A priority patent/IL125620A/en
Priority to DE69713295T priority patent/DE69713295T2/de
Priority to RU98117804A priority patent/RU2172739C2/ru
Priority to TR1998/01642T priority patent/TR199801642T2/xx
Priority to HK99102514.5A priority patent/HK1017357B/xx
Priority to EP97905544A priority patent/EP0885221B1/en
Priority to CZ19982659A priority patent/CZ289110B6/cs
Priority to EE9800250A priority patent/EE9800250A/xx
Priority to PL97328614A priority patent/PL328614A1/xx
Priority to BR9707616A priority patent/BR9707616A/pt
Priority to NZ331145A priority patent/NZ331145A/en
Priority to US08/836,143 priority patent/US5998429A/en
Priority to AU22387/97A priority patent/AU706944B2/en
Priority to NO983711A priority patent/NO983711L/no
Priority to IS4830A priority patent/IS4830A/is
Priority to US09/276,689 priority patent/US6054464A/en
Priority to IL13758500A priority patent/IL137585A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/027—Organoboranes and organoborohydrides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • General Health & Medical Sciences (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
SE9600683A 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy SE9600683D0 (sv)

Priority Applications (29)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy
ZA9701082A ZA971082B (en) 1996-02-23 1997-02-10 Azabicyclic esters of carbamic acids useful in therapy.
ARP970100618A AR005876A1 (es) 1996-02-23 1997-02-17 Esteres azabiciclicos de acidos carbamicos utiles en terapia, composicion farmaceutica que incluye a dichos esteres, uso de dichos esteres, metodos parael tratamiento o profilaxis de varios desordenes, enfermedades y adicciones, procedimiento para la preparacion de dichos esteres, intermediarios utilizados
IDP970487A ID15969A (id) 1996-02-23 1997-02-20 Ester azabisiklik asam karbamat yang berguna dalam terapi.
AU22387/97A AU706944B2 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
IL12562097A IL125620A (en) 1996-02-23 1997-02-21 Azabicyclic esters of cereal phenylic and pyridylic acids, their preparations and medicinal preparations containing them
EP97905544A EP0885221B1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
KR1019980706579A KR19990087184A (ko) 1996-02-23 1997-02-21 치료에 유용한 카르밤산의 아자비시클릭 에스테르
CN97192461A CN1063749C (zh) 1996-02-23 1997-02-21 用于治疗的氨基甲酸的氮杂双环酯
HU9901273A HUP9901273A3 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
PCT/SE1997/000294 WO1997030998A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
JP9530075A JP2000505452A (ja) 1996-02-23 1997-02-21 治療に有用なカルバミン酸のアザビシクロエステル
AT97905544T ATE219081T1 (de) 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
SK1027-98A SK102798A3 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
DE69713295T DE69713295T2 (de) 1996-02-23 1997-02-21 Azabicyclishe carbaniumsaureester zur therapeutsichen verwendung
RU98117804A RU2172739C2 (ru) 1996-02-23 1997-02-21 Азабициклические сложные эфиры карбаминовых кислот, способы их получения, фармацевтическая композиция и промежуточные соединения
TR1998/01642T TR199801642T2 (xx) 1996-02-23 1997-02-21 Tedavide faydal� olan karbamik asitlerin azabisiklik esterleri.
HK99102514.5A HK1017357B (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
CA002246051A CA2246051A1 (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
CZ19982659A CZ289110B6 (cs) 1996-02-23 1997-02-21 Azabicyklické estery pro léčení poruch psychotických nebo naruąení intelektu
EE9800250A EE9800250A (et) 1996-02-23 1997-02-21 Teraapias kasutatavad karbaamhapete asabitsüklilised estrid
PL97328614A PL328614A1 (en) 1996-02-23 1997-02-21 Azabicyclic carbaminic esters useful in therapy
BR9707616A BR9707616A (pt) 1996-02-23 1997-02-21 Composto composiç o farmacéutica utilização de um composto e processo para a preparação de um composto para o tratamento ou profilaxia de distúrbios de deficiéncia intelectual ou profilaxia da doença de parkinson doença de huntington síndrome de tourette esclerose amiotrófica lateral ou distúrbios neurodegenerativos
NZ331145A NZ331145A (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in treating disorders involving reduced cholinergic function
US08/836,143 US5998429A (en) 1996-02-23 1997-02-21 Azabicyclic esters of carbamic acids useful in therapy
NO983711A NO983711L (no) 1996-02-23 1998-08-13 Azabicykliske estere av karbaminsyrer som er nyttige i terapi
IS4830A IS4830A (is) 1996-02-23 1998-08-20 Asabísýklískir esterar af karbamiksýrum sem eru gagnlegir við læknismeðferð
US09/276,689 US6054464A (en) 1996-02-23 1999-03-26 Azabicyclic esters of carbamic acids useful in therapy
IL13758500A IL137585A0 (en) 1996-02-23 2000-07-30 Azabicyclic esters of phenyl and pyridyl carbamic adics, their preparation and pharmaceutical compositions containing them

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy

Publications (1)

Publication Number Publication Date
SE9600683D0 true SE9600683D0 (sv) 1996-02-23

Family

ID=20401517

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9600683A SE9600683D0 (sv) 1996-02-23 1996-02-23 Azabicyclic esters of carbamic acids useful in therapy

Country Status (26)

Country Link
US (2) US5998429A (cs)
EP (1) EP0885221B1 (cs)
JP (1) JP2000505452A (cs)
KR (1) KR19990087184A (cs)
CN (1) CN1063749C (cs)
AR (1) AR005876A1 (cs)
AT (1) ATE219081T1 (cs)
AU (1) AU706944B2 (cs)
BR (1) BR9707616A (cs)
CA (1) CA2246051A1 (cs)
CZ (1) CZ289110B6 (cs)
DE (1) DE69713295T2 (cs)
EE (1) EE9800250A (cs)
HU (1) HUP9901273A3 (cs)
ID (1) ID15969A (cs)
IL (2) IL125620A (cs)
IS (1) IS4830A (cs)
NO (1) NO983711L (cs)
NZ (1) NZ331145A (cs)
PL (1) PL328614A1 (cs)
RU (1) RU2172739C2 (cs)
SE (1) SE9600683D0 (cs)
SK (1) SK102798A3 (cs)
TR (1) TR199801642T2 (cs)
WO (1) WO1997030998A1 (cs)
ZA (1) ZA971082B (cs)

Families Citing this family (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5977144A (en) * 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
US7214686B2 (en) 1997-06-30 2007-05-08 Targacept, Inc. Pharmaceutical compositions and methods for effecting dopamine release
US6632823B1 (en) * 1997-12-22 2003-10-14 Merck & Co., Inc. Substituted pyridine compounds useful as modulators of acetylcholine receptors
US6277870B1 (en) 1998-05-04 2001-08-21 Astra Ab Use
FR2804430B1 (fr) * 2000-01-28 2002-03-22 Sanofi Synthelabo Derives de 4-heteroaryl-1,4-diazabicyclo[3.2.2] nonane, leur preparation et leur application en therapeutique
GB0010955D0 (en) 2000-05-05 2000-06-28 Novartis Ag Organic compounds
US8914114B2 (en) 2000-05-23 2014-12-16 The Feinstein Institute For Medical Research Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
US6492385B2 (en) 2000-08-18 2002-12-10 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
AU2001284645A1 (en) * 2000-08-18 2002-03-04 Pharmacia And Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
US6486172B2 (en) 2000-08-18 2002-11-26 Pharmacia & Upjohn Company Quinuclidine-substituted aryl compounds for treatment of disease
EP1381603A2 (en) 2000-08-18 2004-01-21 PHARMACIA & UPJOHN COMPANY Quinuclidine-substituedaryl moieties for treatment of disease ( nicotinic acetylcholine receptor ligands )
WO2002016355A2 (en) * 2000-08-21 2002-02-28 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic) acetylcholine receptor ligands
US6599916B2 (en) 2000-08-21 2003-07-29 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
US6500840B2 (en) 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
PE20021019A1 (es) 2001-04-19 2002-11-13 Upjohn Co Grupos azabiciclicos sustituidos
AR036041A1 (es) * 2001-06-12 2004-08-04 Upjohn Co Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
AR036040A1 (es) 2001-06-12 2004-08-04 Upjohn Co Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
US6562816B2 (en) 2001-08-24 2003-05-13 Pharmacia & Upjohn Company Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
CA2455773A1 (en) * 2001-08-24 2003-03-06 Pharmacia & Upjohn Company Substituted-aryl 7-aza¬2.2.1|bicycloheptanes for the treatment of disease
DE60218493D1 (de) * 2001-09-12 2007-04-12 Pharmacia & Upjohn Co Llc Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
BR0213612A (pt) 2001-10-02 2004-08-24 Upjohn Co Composto, composição farmacêutica, uso do composto e método para tratamento de doença ou condição
US6849620B2 (en) 2001-10-26 2005-02-01 Pfizer Inc N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
CA2466375A1 (en) 2001-11-08 2003-05-15 Pharmacia & Upjohn Company Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
CA2466344A1 (en) * 2001-11-09 2003-05-22 Pharmacia & Upjohn Company Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
BR0214929A (pt) 2001-12-14 2006-05-30 Targacept Inc métodos e composições para o tratamento de distúrbios do sistema nervoso central
DE10164139A1 (de) 2001-12-27 2003-07-10 Bayer Ag 2-Heteroarylcarbonsäureamide
EP1480977A2 (en) 2002-02-15 2004-12-01 PHARMACIA & UPJOHN COMPANY Substituted aryl compounds for treatment of disease
MXPA04008152A (es) * 2002-02-19 2005-09-08 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
CA2476681A1 (en) * 2002-02-19 2003-08-28 Bruce N. Rogers Fused bicyclic-n-bridged-heteroaromatic carboxamides for the treatment of disease
JP2005525357A (ja) * 2002-02-20 2005-08-25 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー α７ニコチン性アセチルコリン受容体活性を伴うアザ二環式化合物
DE10211416A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Essig- und Propionsäureamide
DE10211415A1 (de) * 2002-03-15 2003-09-25 Bayer Ag Bicyclische N-Biarylamide
AU2003253686A1 (en) 2002-08-01 2004-02-23 Pharmacia & Upjohn Company Llc 1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
EP2305664A1 (en) 2002-08-30 2011-04-06 Memory Pharmaceuticals Corporation Anabaseine derivatives useful in the treatment of neurodegeneratives diseases
GB0220581D0 (en) 2002-09-04 2002-10-09 Novartis Ag Organic Compound
AU2003276919B2 (en) 2002-09-25 2013-05-16 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
EP1562959A2 (en) * 2002-11-01 2005-08-17 Pharmacia & Upjohn Company LLC Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
US7238715B2 (en) 2002-12-06 2007-07-03 The Feinstein Institute For Medical Research Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
CN102657651A (zh) 2002-12-06 2012-09-12 范因斯坦医学研究院 用α 7受体结合胆碱能激动剂抑制炎症
JP2006521345A (ja) * 2003-03-28 2006-09-21 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー ニコチン性アセチルコリン受容体の正のアロステリック調節剤
GB0310867D0 (en) 2003-05-12 2003-06-18 Novartis Ag Organic compounds
DE10334724A1 (de) 2003-07-30 2005-02-24 Bayer Healthcare Ag N-Biarylamide
US7402592B2 (en) 2003-10-15 2008-07-22 Targacept, Inc. Pharmaceutical compositions and methods for relieving pain and treating central nervous system disorders
FR2861076B1 (fr) * 2003-10-17 2006-01-06 Sanofi Synthelabo Derives de n-heterocyclymethylbenzamide, leur preparation et leur application en therapeutique
US20050137217A1 (en) * 2003-12-22 2005-06-23 Jianguo Ji Spirocyclic quinuclidinic ether derivatives
PT1697378E (pt) 2003-12-22 2008-02-28 Memory Pharm Corp Indoles, 1h-indazoles, 1,2-benzisoxazoles e 1,2-benzisotiazoles, sua preparação e utilizações
FR2865208B1 (fr) * 2004-01-16 2009-01-16 Sanofi Synthelabo Derives de 1,4-diazabicyclo[3.2.1]octanecarboxmique, leur preparation et leur application en therapeutique
EP1735306A2 (en) 2004-03-25 2006-12-27 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
US10912712B2 (en) 2004-03-25 2021-02-09 The Feinstein Institutes For Medical Research Treatment of bleeding by non-invasive stimulation
WO2006001894A1 (en) 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
EP1745046B1 (en) 2004-05-07 2011-04-13 Memory Pharmaceuticals Corporation 1 h-indazoles, benzothiazoles, 1,2-benziosoxazoles, 1,2-benzoisothiazoles, and chromones and preparation and uses thereof
AR049401A1 (es) 2004-06-18 2006-07-26 Novartis Ag Aza-biciclononanos
GB0415746D0 (en) 2004-07-14 2004-08-18 Novartis Ag Organic compounds
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
KR20070087674A (ko) 2004-12-22 2007-08-28 메모리 파마슈티칼스 코포레이션 니코틴 α-７ 수용체 리간드 및 이의 제조 및 용도
CA2593079C (en) 2004-12-27 2014-08-19 North Shore-Long Island Jewish Research Institute Treating inflammatory disorders by electrical vagus nerve stimulation
US11207518B2 (en) 2004-12-27 2021-12-28 The Feinstein Institutes For Medical Research Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
US7732607B2 (en) 2005-08-22 2010-06-08 Anatoly Mazurov Heteroaryl-substituted diazatricycloalkanes and methods of use thereof
US8106066B2 (en) 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
GB0521508D0 (en) 2005-10-21 2005-11-30 Novartis Ag Organic compounds
US8316104B2 (en) 2005-11-15 2012-11-20 California Institute Of Technology Method and apparatus for collaborative system
GB0525672D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
GB0525673D0 (en) 2005-12-16 2006-01-25 Novartis Ag Organic compounds
TWI404532B (zh) * 2006-11-02 2013-08-11 Targacept Inc 菸鹼乙醯膽鹼受體亞型選擇性之二氮雜雙環烷類醯胺
TW200901974A (en) 2007-01-16 2009-01-16 Wyeth Corp Compounds, compositions, and methods of making and using them
BRPI0806972A2 (pt) 2007-02-09 2014-04-08 Astellas Pharma Inc Composto cíclico contendo ponte azo
WO2009013535A1 (en) * 2007-07-23 2009-01-29 Astrazeneca Ab 2-azabicyclo(2.2.2)octane derivatives as modulators of the glycine transporter i receptor
SA08290475B1 (ar) * 2007-08-02 2013-06-22 Targacept Inc (2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
US8391970B2 (en) 2007-08-27 2013-03-05 The Feinstein Institute For Medical Research Devices and methods for inhibiting granulocyte activation by neural stimulation
EP2217597B1 (en) 2007-10-01 2011-03-30 Comentis, Inc. Quinuclidin-4-ylmethyl 1h-indole-3-carboxylate derivatives as alpha 7 nicotinic acetylcholine receptor ligands for the treatment of alzheimer's disease
DK2254598T3 (da) 2008-02-13 2013-07-29 Targacept Inc Kombination af alfa 7-nikotinagonister og antipsykotika
US9662490B2 (en) 2008-03-31 2017-05-30 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
WO2009146030A1 (en) 2008-03-31 2009-12-03 The Feinstein Institute For Medical Research Methods and systems for reducing inflammation by neuromodulation of t-cell activity
CA2728675A1 (en) 2008-06-20 2009-12-23 Astrazeneca Ab Dibenzothiazepine derivatives and use thereof
AU2009316801C1 (en) 2008-11-18 2015-12-24 Setpoint Medical Corporation Devices and methods for optimizing electrode placement for anti-inflammatory stimulation
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
UY32397A (es) * 2009-01-28 2010-08-31 Astrazeneca Ab Compuestos de 2-aza-biciclo [2,2,1] heptano y sus usos
US8996116B2 (en) 2009-10-30 2015-03-31 Setpoint Medical Corporation Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
US9211410B2 (en) 2009-05-01 2015-12-15 Setpoint Medical Corporation Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
CN102573986B (zh) 2009-06-09 2016-01-20 赛博恩特医疗器械公司 用于无导线刺激器的具有袋部的神经封套
FR2948368B1 (fr) * 2009-07-21 2011-07-22 Servier Lab Nouveaux composes piperidiniques, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US9833621B2 (en) 2011-09-23 2017-12-05 Setpoint Medical Corporation Modulation of sirtuins by vagus nerve stimulation
US11051744B2 (en) 2009-11-17 2021-07-06 Setpoint Medical Corporation Closed-loop vagus nerve stimulation
CN102821814B (zh) 2009-12-23 2015-07-15 赛博恩特医疗器械公司 用于治疗慢性炎症的神经刺激设备和系统
JP5749797B2 (ja) 2010-05-17 2015-07-15 フォルム ファーマシューティカルズ、インコーポレイテッド （ｒ）−７−クロロ−ｎ−（キヌクリジン−３−イル）ベンゾ［ｂ］チオフェン−２−カルボキサミド塩酸塩一水和物の結晶形
MX353096B (es) 2010-08-19 2017-12-19 Buck Institute For Age Res Star Metodos para tratar el deterioro cognitivo leve (mci) y trastornos relacionados.
EP2707094B1 (en) 2011-05-09 2016-02-03 Setpoint Medical Corporation Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
US12172017B2 (en) 2011-05-09 2024-12-24 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
GB201111704D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Novel compounds
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
JO3115B1 (ar) 2011-08-22 2017-09-20 Takeda Pharmaceuticals Co مركبات بيريدازينون واستخدامها كمثبطات daao
US9572983B2 (en) 2012-03-26 2017-02-21 Setpoint Medical Corporation Devices and methods for modulation of bone erosion
MX358512B (es) 2012-05-08 2018-08-24 Forum Pharmaceuticals Inc Uso de (r)-7cloro-n-(quinuclidin-3-il) benzo[b] tiofeno-2-carboxamida o una sal farmacéuticamente aceptable de la misma para preparar una composición farmacéutica en el tratamiento de una disfunción cognitiva.
GB201209587D0 (en) 2012-05-30 2012-07-11 Takeda Pharmaceutical Therapeutic compounds
MA37975B2 (fr) * 2012-09-11 2021-03-31 Genzyme Corp Inhibiteurs de synthase de glucosylcéramide
CN105189482A (zh) 2013-02-07 2015-12-23 武田药品工业株式会社 作为毒蕈碱m4受体激动剂的哌啶-1-基羧酸酯和氮杂卓-1-基羧酸酯
AR095436A1 (es) * 2013-03-15 2015-10-14 Genzyme Corp Procedimiento para preparar inhibidores de la glucosilceramida sintasa
AU2014282977B2 (en) 2013-06-21 2018-06-14 Takeda Pharmaceutical Company Limited 1-sulfonyl piperidine derivatives as modulators of prokineticin receptors
GB201314286D0 (en) 2013-08-08 2013-09-25 Takeda Pharmaceutical Therapeutic Compounds
GB201318222D0 (en) 2013-10-15 2013-11-27 Takeda Pharmaceutical Novel compounds
GB201320905D0 (en) 2013-11-27 2014-01-08 Takeda Pharmaceutical Therapeutic compounds
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
US20170166561A1 (en) 2014-07-11 2017-06-15 Alpharmagen, Llc Quinuclidine compounds for modulating alpha7-nicotinic acetylcholine receptor activity
US11311725B2 (en) 2014-10-24 2022-04-26 Setpoint Medical Corporation Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
WO2016126807A1 (en) 2015-02-03 2016-08-11 Setpoint Medical Corporation Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
US9724340B2 (en) 2015-07-31 2017-08-08 Attenua, Inc. Antitussive compositions and methods
US10596367B2 (en) 2016-01-13 2020-03-24 Setpoint Medical Corporation Systems and methods for establishing a nerve block
EP3405255A4 (en) 2016-01-20 2019-10-16 Setpoint Medical Corporation IMPLANTABLE MICROSTIMULATORS AND INDUCTIVE CHARGING SYSTEMS
US11471681B2 (en) 2016-01-20 2022-10-18 Setpoint Medical Corporation Batteryless implantable microstimulators
CN108882885A (zh) 2016-01-20 2018-11-23 赛博恩特医疗器械公司 迷走神经刺激的控制
US10583304B2 (en) 2016-01-25 2020-03-10 Setpoint Medical Corporation Implantable neurostimulator having power control and thermal regulation and methods of use
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
GB201619514D0 (en) 2016-11-18 2017-01-04 Takeda Pharmaceuticals Co Novel compounds
DE102017210141A1 (de) 2017-06-16 2018-12-20 Henkel Ag & Co. Kgaa Portion zur Bereitstellung tensidhaltiger Flotten
WO2019036470A1 (en) 2017-08-14 2019-02-21 Setpoint Medical Corporation TESTING TEST FOR STIMULATION OF NERVE WAVE
US11660443B2 (en) 2018-04-20 2023-05-30 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
US11260229B2 (en) 2018-09-25 2022-03-01 The Feinstein Institutes For Medical Research Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
WO2020210786A1 (en) 2019-04-12 2020-10-15 Setpoint Medical Corporation Vagus nerve stimulation to treat neurodegenerative disorders
KR20210059634A (ko) * 2019-11-15 2021-05-25 주식회사유한양행 글루코실세라마이드 합성효소에 대한 저해 활성을 갖는 신규의 화합물 또는 이의 약학적으로 허용가능한 염, 이의 제조방법, 및 이를 포함하는 약학 조성물
CN114829361B (zh) * 2019-11-15 2024-07-16 柳韩洋行 具有2,3-二氢-1h-茚或2,3-二氢苯并呋喃部分的衍生物或其药学上可接受盐及含其的药物组合物
WO2021156769A1 (en) 2020-02-03 2021-08-12 Genzyme Corporation Methods for treating neurological symptoms associated with lysosomal storage diseases
JP2021138648A (ja) 2020-03-04 2021-09-16 武田薬品工業株式会社 経口固形製剤
EP4566539A1 (en) 2020-05-21 2025-06-11 The Feinstein Institutes for Medical Research Systems and methods for vagus nerve stimulation
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.
MX2023012541A (es) * 2021-05-11 2023-11-03 Yuhan Corp Nuevos compuestos con actividad inhibidora contra la glucosilceramida sintasa o su sal farmaceuticamente aceptable, procedimientos para prepararlos y composiciones farmaceuticas que los contengan.
IL319915A (en) * 2022-10-24 2025-05-01 Yuhan Corp Improved processes for the preparation of dimethyl-3,2-dihydro-1H-indene derivatives
CN119816498A (zh) * 2022-10-24 2025-04-11 柳韩洋行 二甲基-2,3-二氢-1h-茚衍生物的新型盐及其制备方法
KR20250117295A (ko) * 2024-01-26 2025-08-04 주식회사유한양행 고셔병의 예방 또는 치료용 약제학적 조성물

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU482990A1 (ru) * 1973-09-03 1978-04-15 Предприятие П/Я Г-4059 Способ получени 1,4-диазабицикло(2,2,2)-октана
DE8817121U1 (de) * 1988-11-22 1993-02-04 Boehringer Ingelheim Kg, 55218 Ingelheim Neue Quinuclidine
JP3169188B2 (ja) * 1991-01-31 2001-05-21 杏林製薬株式会社 カルバミン酸誘導体及びその製造方法
US5530018A (en) * 1994-02-04 1996-06-25 G. D. Searle & Co. Meso-azanoradamantanes
US5468875A (en) * 1994-12-22 1995-11-21 American Home Products Corporation 1-azabicycloheptane derivatives

Also Published As

Publication number Publication date
PL328614A1 (en) 1999-02-01
CZ289110B6 (cs) 2001-11-14
HUP9901273A3 (en) 2000-06-28
DE69713295T2 (de) 2003-01-09
AU2238797A (en) 1997-09-10
CN1063749C (zh) 2001-03-28
EP0885221B1 (en) 2002-06-12
RU2172739C2 (ru) 2001-08-27
ID15969A (id) 1997-08-21
NO983711D0 (no) 1998-08-13
US6054464A (en) 2000-04-25
NZ331145A (en) 2000-02-28
ZA971082B (en) 1997-08-25
CN1211983A (zh) 1999-03-24
HUP9901273A2 (hu) 1999-07-28
DE69713295D1 (de) 2002-07-18
BR9707616A (pt) 1999-07-27
EP0885221A1 (en) 1998-12-23
WO1997030998A1 (en) 1997-08-28
ATE219081T1 (de) 2002-06-15
AU706944B2 (en) 1999-07-01
IL137585A0 (en) 2001-07-24
TR199801642T2 (xx) 1998-11-23
CA2246051A1 (en) 1997-08-28
SK102798A3 (en) 1999-01-11
IL125620A0 (en) 1999-04-11
IS4830A (is) 1998-08-20
US5998429A (en) 1999-12-07
EE9800250A (et) 1999-02-15
NO983711L (no) 1998-08-13
JP2000505452A (ja) 2000-05-09
HK1017357A1 (en) 1999-11-19
AR005876A1 (es) 1999-07-21
CZ265998A3 (cs) 2000-02-16
KR19990087184A (ko) 1999-12-15
IL125620A (en) 2001-09-13

Similar Documents

Publication Publication Date Title
SE9600683D0 (sv) Azabicyclic esters of carbamic acids useful in therapy
ATE63742T1 (de) Chinazolinon-derivate.
ATE399753T1 (de) Amide als pyruvatdehydrogenaseinhibitoren
MX2022000244A (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas.
TW370529B (en) Pyrazolopyrimidines
EA200500018A1 (ru) Бензконденсированные гетероариламидные производные тиенопиридинов, применяемые в качестве терапевтических агентов, фармацевтические композиции, включающие их, и способы их применения
SE9701144D0 (sv) Novel compounds, their use and preparation
SE0104334D0 (sv) Therapeutic agents
MY119542A (en) Therapeutic biaryl derivatives
HUP0001760A2 (hu) Aril-acil-piridazin-származékok, ezeket a vegyületeket tartalmazó gyógyászati készítmények, eljárás előállításukra és a vegyületek alkalmazása gyógyszerkészítmények előállítására
AP1564A (en) Piperazinyl sulfonic acid derivatives, their pharmaceutical compositions and methods of use.
NZ528997A (en) Sulfonamides
NO160995C (no) Analogifremgangsmaate for fremstilling av terapeutisk aktive bis -(4-aminofenyl)-sulfoner.
ES8606337A1 (es) Un procedimiento para preparar nuevas benzamidas con actividada antagonista de 5-ht.
NO160783C (no) Analogifremgangsmaate til fremstilling av terapeutisk aktive substituerte beta-karbolinderivater.
ES2000524A6 (es) Procedimiento para la preparacion de nuevas benzamidas y benzoatos sustituidos.
SE0104333D0 (sv) Therapeutic agents
PT1430034E (pt) Derivados de alquilaminopiridazinona substituida processo para sua preparacao e composicoes farmaceuticas que os contem
EA200500738A1 (ru) КРИСТАЛЛИЧЕСКИЕ ФУМАРАТНЫЕ СОЛИ 1-АЗАБИЦИКЛО [2.2.2]ОКТЗАМЕЩЕННОГО ФУРО [2,3-c] ПИРИДИНИЛКАРБОКСАМИДА И ИХ КОМПОЗИЦИИ И ПОЛУЧЕНИЕ
ES8801212A1 (es) Un procedimiento para preparar 5,8,13,14-tetrahido-(9- y 12 -hidroxi)-14-metilben (5,6)-isoindolo (2,1-b)isoquinolin-8,13-diona
ES8101045A1 (es) Procedimiento para la preparacion de derivados de acidos pi-rrolidinilsulfamoilbenzoicos sustituidos
HUP9800889A1 (hu) Új naftil-piperazin-származékok
ATE41770T1 (de) Derivate von n-(2-pyrrolidinylmethyl)benzamid, verfahren zu ihrer herstellung, zwischenprodukte und pharmazeutische zubereitung.
MX9601953A (es) Nuevo compesto derivados de 5h-tiazolo [3,2-a] pirimidin-5-ona.